Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

EJHaem

Showing results (591-600 of 930) with videos related to

Pageof 93
Sort By:
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Ejhaem|October 17, 2024
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemiaNilesh Kapoor, Qiuhong Zhao, Andrew Stiff, et al.
Ejhaem|October 17, 2024
Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemiaIngrid Glimelius, Geffen Kleinstern, Dennis P Robinson, et al.
Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Ejhaem|October 17, 2024
Myeloma-associated hemophagocytic lymphohistiocytosis - A comprehensive case study and a novel chemotherapy-free approach with anakinraMaged Al-Ammari, Danny Hsu, Adam Bryant
Ejhaem|October 17, 2024
Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case reportAurélie Briane, Valérie Horvais, Marianne Sigaud, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
Ejhaem|August 19, 2024
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case reportAnna Nikkarinen, Ingrid Glimelius
Ejhaem|August 19, 2024
Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in AfricaZekarias Seifu Ayalew, Gebeyehu Tessema Azibte, Fisihatsion Tadesse, et al.
Pageof 93

Showing results (591-600 of 930) with videos related to

Sort By:
Pageof 93
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Ejhaem|October 17, 2024
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemiaNilesh Kapoor, Qiuhong Zhao, Andrew Stiff, et al.
Ejhaem|October 17, 2024
Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemiaIngrid Glimelius, Geffen Kleinstern, Dennis P Robinson, et al.
Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Ejhaem|October 17, 2024
Myeloma-associated hemophagocytic lymphohistiocytosis - A comprehensive case study and a novel chemotherapy-free approach with anakinraMaged Al-Ammari, Danny Hsu, Adam Bryant
Ejhaem|October 17, 2024
Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case reportAurélie Briane, Valérie Horvais, Marianne Sigaud, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
Ejhaem|August 19, 2024
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case reportAnna Nikkarinen, Ingrid Glimelius
Ejhaem|August 19, 2024
Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in AfricaZekarias Seifu Ayalew, Gebeyehu Tessema Azibte, Fisihatsion Tadesse, et al.
Pageof 93